Editas Medicine Ownership
| EDIT Stock | USD 2.38 0.06 2.46% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 82 M | Current Value 82 M | Avarage Shares Outstanding 51.3 M | Quarterly Volatility 22.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Editas |
Editas Stock Ownership Analysis
About 70.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.15. Some equities with similar Price to Book (P/B) outperform the market in the long run. Editas Medicine recorded a loss per share of 2.54. The entity had not issued any dividends in recent years. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people. To learn more about Editas Medicine call Gilmore MD at 617 401 9000 or check out https://www.editasmedicine.com.Besides selling stocks to institutional investors, Editas Medicine also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Editas Medicine's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Editas Medicine's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Editas Medicine Quarterly Liabilities And Stockholders Equity |
|
Editas Medicine Insider Trades History
Less than 1% of Editas Medicine are currently held by insiders. Unlike Editas Medicine's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Editas Medicine's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Editas Medicine's insider trades
Editas Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Editas Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Editas Medicine backward and forwards among themselves. Editas Medicine's institutional investor refers to the entity that pools money to purchase Editas Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 1.2 M | Woodline Partners Lp | 2024-06-30 | 970.5 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 897.5 K | Two Sigma Advisers, Llc | 2024-06-30 | 856.5 K | Jpmorgan Chase & Co | 2024-06-30 | 799.2 K | Northern Trust Corp | 2024-09-30 | 703.8 K | Squarepoint Ops Llc | 2024-06-30 | 694.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 617.3 K | Raymond James & Associates | 2024-09-30 | 561.4 K | Blackrock Inc | 2024-06-30 | 7.8 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
Editas Medicine Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Editas Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Editas Medicine Outstanding Bonds
Editas Medicine issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Editas Medicine uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Editas bonds can be classified according to their maturity, which is the date when Editas Medicine has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US281020AN70 Corp BondUS281020AN70 | View | |
| EDISON INTL 4125 Corp BondUS281020AM97 | View | |
| EIX 5 Corp BondUS281020AT41 | View | |
| EIX 5375 Corp BondUS281020AS67 | View | |
| US281020AR84 Corp BondUS281020AR84 | View | |
| US281020AQ02 Corp BondUS281020AQ02 | View |
Editas Medicine Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 16th of April 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.